Clinical outcomes and immune phenotypes associated with STK11 co-occurring mutations in non-small cell lung cancer.

ABSTRACT:

Background

STK11 mutation in non-small cell lung cancer (NSCLC) is associated with worse survival as well as primary resistance to PD-1/PD-L1 targeting immunotherapy. We hypothesize that co-occurring mutations and tumor mutation burden (TMB) may impact response to therapy and prognosis.

Methods

Forty-one patients with STK11-mutated NSCLC seen in our Thoracic oncology clinic with available next-generation sequencing tumor data were included in the analysis. Data from the Cancer Genome Atlas (TCGA) was used for survival and immune gene expression analysis. Overall and progression-free survival (PFS) was estimated by the Kaplan-Meier method and compared using a log-rank test.

Results

In the 41 patients included, common co-occurring alterations with STK11

SUBMITTER: Malhotra J 

PROVIDER: S-EPMC9264081 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature